Actas urologicas espanolas最新文献

{"title":"Can we use intense intravesical neoadjuvant chemotherapy to treat recurrent LG-IR NMIBC and avoid TURBT?","authors":"G. Villoldo , A. Kamat , G. Fernández Candia","doi":"10.1016/j.acuroe.2025.501829","DOIUrl":"10.1016/j.acuroe.2025.501829","url":null,"abstract":"","PeriodicalId":94291,"journal":{"name":"Actas urologicas espanolas","volume":"50 4","pages":"Article 501829"},"PeriodicalIF":0.0,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144777475","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on “Analysis of device survival and predictive factors in a cohort of patients undergoing male artificial urinary sphincter implantation”. Authors’ reply","authors":"C. Minguez Ojeda, A. Artiles Medina","doi":"10.1016/j.acuroe.2025.501840","DOIUrl":"10.1016/j.acuroe.2025.501840","url":null,"abstract":"","PeriodicalId":94291,"journal":{"name":"Actas urologicas espanolas","volume":"50 4","pages":"Article 501840"},"PeriodicalIF":0.0,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145058867","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact of multidisciplinary team meetings on the management of metastatic prostate cancer in a reference center","authors":"L.A. Pereira do Nascimento ,&nbsp;R.M. Mariano da Costa Junior ,&nbsp;V. Ramos Machado ,&nbsp;J.J. Saab Filho ,&nbsp;M.H. Bueno Bavaresco ,&nbsp;R. Panhoca ,&nbsp;W. Aparecido França ,&nbsp;L.A. Seabra Rios ,&nbsp;G. Pinheiro Soares","doi":"10.1016/j.acuroe.2026.501905","DOIUrl":"10.1016/j.acuroe.2026.501905","url":null,"abstract":"<div><h3>Introduction</h3><div>The management of metastatic prostate cancer (MPC) is complex and requires timely, coordinated decision-making across multiple specialties. Multidisciplinary team meetings (MDMs) have been increasingly adopted to optimize treatment planning, yet evidence regarding their impact on objective clinical outcomes in genitourinary cancers remains limited.</div></div><div><h3>Methods</h3><div>This retrospective, single-center cohort study compared two periods of MPC care: before MDM implementation (2018–2019) and after implementation (2021–2022). Patients were identified through institutional records. Demographic data, treatment timelines, therapeutic choices, and follow-up patterns were collected. Primary outcomes included time to clinical oncology consultation, time to treatment initiation, systemic therapy use, and follow-up adherence.</div></div><div><h3>Results</h3><div>One hundred thirty-nine patients were included, 72 in the 2018–2019 period and 67 in the 2021–2022 period. There was a significant reduction in the time taken to consult clinical oncology (<em>P</em> &lt; .05) and to start treatment (<em>P</em> &lt; .05). Systemic therapy started predominantly in the castration-sensitive setting (70.2% vs 14.3%; <em>P</em> &lt; .001). The MDM promoted a higher quality of treatment, with a greater prescription of docetaxel and novel antiandrogens (95.7% vs 64.3%; <em>P</em> = .001) and zoledronic acid in the castration-resistant phase (92.5% vs 79.2%; <em>P</em> = .047). The MDM discussion optimized follow-up, with loss to follow-up observed in only 7.5% of cases (<em>P</em> &lt; .001).</div></div><div><h3>Conclusion</h3><div>The implementation of multidisciplinary team meetings significantly improved the timeliness, quality, and adherence to oncological care for patients with metastatic prostate cancer. MDMs should be incorporated as a standard component of care in institutions managing this population.</div></div>","PeriodicalId":94291,"journal":{"name":"Actas urologicas espanolas","volume":"50 4","pages":"Article 501905"},"PeriodicalIF":0.0,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145919614","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Confirmatory MRI and re-biopsy findings during active surveillance in patients with grade group 2 prostate cancer","authors":"F. Sanguedolce ,&nbsp;M. Baboudjian ,&nbsp;A. Redondo Ríos ,&nbsp;R. Leni ,&nbsp;M. Oderda ,&nbsp;A. Peyrottes ,&nbsp;C. Kesch ,&nbsp;M. Al-Nader ,&nbsp;A. Uleri ,&nbsp;T. Long-Depaquit ,&nbsp;C. Dariane ,&nbsp;H. Baud ,&nbsp;J. Olivier ,&nbsp;V. Benard ,&nbsp;O. Windisch ,&nbsp;M. Valerio ,&nbsp;G. Gandaglia ,&nbsp;G. Ploussard","doi":"10.1016/j.acuroe.2026.501924","DOIUrl":"10.1016/j.acuroe.2026.501924","url":null,"abstract":"<div><h3>Introduction</h3><div>To report the results of confirmatory MRI/biopsy in a European cohort of MRI-selected patients with Gleason Grade Group (GG) 2 prostate cancer (PCa) in active surveillance (AS).</div></div><div><h3>Methods</h3><div>Multicenter study enrolled patients with GG2 PCa managed by AS between 2016−2024. Serial MRI scans were interpreted according to PRECISE recommendations. Diagnostic accuracy of PRECISE score to predict upgrading on confirmatory biopsy was assessed by calculating sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) with 95% Confident Intervals (CIs).</div></div><div><h3>Results</h3><div>A total of 77 patients with GG2 PCa was included, with a PI-RADS 4−5 in 48 patients (63%). On confirmatory MRI, 32 cases were classified as PRECISE 4−5 (42%). On confirmatory biopsy, 39 patients (51%) were downgraded to GG0-1, 27 patients (35%) were GG 2 and upgrading occurred in 11 cases (14%). Sensitivity, specificity, NPV and PPV of the PRECISE score 4−5 to detect upgrading was 63.6% (95%CI 31–89), 62.1% (95%CI, 49–74), 91.1% (95%CI, 82–96) and 21.8% (95%CI, 14–32), respectively. In multivariable Cox hazards regression analysis, downgrading at confirmatory biopsy was significantly associated with a reduced risk of subsequent GG3 reclassification (HR 0.125, 95%CI, 0.277−0.560, <em>p</em> = 0.002) and definitive treatment (HR 0.409, 95%CI, 0.199−0.839, <em>p</em> = 0.015).</div></div><div><h3>Conclusion</h3><div>MRI selection of patients with GG2 PCa in AS allows better initial characterization of the disease. The absence of progression on MRI indicates a very low risk of grade reclassification, but signs of imaging progression are not always predictive of progression and should not be considered alone for prompting active treatment.</div></div>","PeriodicalId":94291,"journal":{"name":"Actas urologicas espanolas","volume":"50 4","pages":"Article 501924"},"PeriodicalIF":0.0,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146055876","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Active surveillance as the treatment of choice for low-risk prostate cancer: Reliability of results obtained through clinical language processing systems and big data","authors":"C. García-Fuentes ,&nbsp;V. Hernández ,&nbsp;J. Arias ,&nbsp;M. López ,&nbsp;E. de la Peña ,&nbsp;A. Guijarro ,&nbsp;E. Pérez-Fernández ,&nbsp;C. Llorente","doi":"10.1016/j.acuroe.2026.501907","DOIUrl":"10.1016/j.acuroe.2026.501907","url":null,"abstract":"<div><h3>Introduction</h3><div>Advances in natural language processing (NLP) technologies have gained prominence for extracting relevant clinical information. Savana is a platform capable of analyzing free-text data and interpreting the content of electronic health records (EHRs).</div></div><div><h3>Objective</h3><div>To validate the results obtained through NLP by Savana from data of patients with prostate cancer (PC) included in active surveillance (AS), compare them with our database, and assess their reliability.</div></div><div><h3>Methods</h3><div>Observational and retrospective study of patients with PC in AS between 2014 and 2022. The results from our database were blinded to Savana. Information from the EHRs was transformed by Savana into analysis-ready data. After an initial evaluation, it was necessary to refine the preliminary results and readjust the variables and terminology to eliminate discrepancies.</div></div><div><h3>Results</h3><div>Of the 2865 patients included in our database, 306 met the selection criteria. Savana detected 366 patients with the terms \"PC,\" \"Gleason,\" and \"AS.\" The results were similar regarding Gleason score at diagnosis: 93.4% Gleason 6 in our series vs. 92% in Savana. Likewise, the proportion of patients who received treatment with curative intent, and the type of treatment were comparable: 33.3% in our series (RP: 56.9%; RT: 42.1%) vs. 32.5% in Savana (RP: 59.7%; RT: 40.3%). However, only 24.8% showed Gleason progression in our series vs. 31% in Savana. The mortality rate was 3.2% in our series vs. 7.4% in Savana.</div></div><div><h3>Conclusions</h3><div>NLP represents a promising tool in clinical research, but its implementation should be approached with caution.</div></div>","PeriodicalId":94291,"journal":{"name":"Actas urologicas espanolas","volume":"50 4","pages":"Article 501907"},"PeriodicalIF":0.0,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145919271","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erectile dysfunction and related variables due to anabolic steroid use. A review of reviews","authors":"M. García Vidal,&nbsp;A. Vázquez Méndez,&nbsp;I. Mollinedo Cardalda,&nbsp;I. De Oliveira","doi":"10.1016/j.acuroe.2026.501926","DOIUrl":"10.1016/j.acuroe.2026.501926","url":null,"abstract":"<div><h3>Introduction and objective</h3><div>Anabolic androgenic steroids are synthetic substances that mimic testosterone, promoting increased strength and muscle mass. Although they were initially used to achieve an increase in sports performance, nowadays most users are not professional athletes. Their use can cause various adverse effects, but despite these, they continue to be used to improve aesthetic and performance aspects. The purpose of this review of reviews was to examine the effects of anabolic androgenic steroids on male erectile function and related variables.</div></div><div><h3>Materials and methods</h3><div>A systematised literature review was carried out in Medline, Scopus, Pubmed, Cinahl, ScienceDirect, SPORTDiscus databases in July 2025. The search terms were ‘Anabolic Androgenic Steroids’, ‘Erectile Dysfunction’ and ‘Adverse effect’. The A Measurement Tool to Assess Systematic Review (AMSTAR-2) was used to assess the methodological quality of the selected reviews.</div></div><div><h3>Results</h3><div>Six systematic reviews were valid. Assessment of methodological quality using the AMSTAR-2 scale revealed that four reviews had critically low confidence, one review had low confidence, and one review had medium confidence. Despite methodological limitations, the reviews showed common findings associating prolonged use of anabolic androgenic steroids with the reduction in hormone levels, testosterone levels and reproductive function, leading to erectile dysfunction, in young adults (28–33 years) involved in weightlifting, powerlifting or bodybuilding.</div></div><div><h3>Conclusions</h3><div>The use of anabolic androgenic steroids appears to have a negative impact on erectile function and male reproductive health, with evidence of hypogonadism and hormonal alterations.</div></div>","PeriodicalId":94291,"journal":{"name":"Actas urologicas espanolas","volume":"50 4","pages":"Article 501926"},"PeriodicalIF":0.0,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146198376","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retrosigmoid ileal conduit versus traditional techniques after radical cystectomy: Impact on the incidence of ureteroileal anastomotic stricture","authors":"C. Casanova-Martín ,&nbsp;M. Álvarez-Maestro ,&nbsp;A. Rodríguez-Serrano ,&nbsp;A. Gómez-Villanueva ,&nbsp;A. Aguilera-Bazán ,&nbsp;M. Serrano-Liesa ,&nbsp;J.M. Alonso-Dorrego ,&nbsp;M.Á. Ortega-Núñez ,&nbsp;E. Ríos-González ,&nbsp;L. Martínez-Piñeiro Lorenzo","doi":"10.1016/j.acuroe.2026.501934","DOIUrl":"10.1016/j.acuroe.2026.501934","url":null,"abstract":"<div><h3>Introduction and objective</h3><div>Ureteroileal anastomotic stricture (UAS) is a relevant complication after radical cystectomy (RC). The retrosigmoid ileal conduit (RIC) may reduce its incidence by avoiding left ureteral transposition.</div></div><div><h3>Objective</h3><div>To compare the incidence of UAS, perioperative outcomes, and length of stay between RIC and conventional urinary diversions (Bricker/Wallace).</div></div><div><h3>Material and methods</h3><div>Retrospective, single-center observational study. All patients undergoing RC with bilateral urinary diversion were included: RIC between 01/2021–12/2024 and conventional techniques between 01/2018–12/2020. <em>Primary variable</em>: Multivariable logistic regression was performed using: age, body mass index (BMI), prior urinary tract dilation, Charlson Comorbidity Index (CCI), Eastern Cooperative Oncology Group (ECOG) score, and surgical technique. <em>Secondary variables</em>: operative time, 30-day postoperative complications (grouped as minor complications [Clavien 1-2] and major complications [Clavien ≥3]), time to stricture, length of hospital stay, and follow-up time after surgery.</div></div><div><h3>Results</h3><div>Seventy-one patients were analyzed: 36 RIC and 35 controls, with comparable baseline characteristics. UAS presented an incidence of 2.8% in RIC group and 22.9% in controls; the RIC technique was associated with a lower adjusted risk (OR: 0.05; 95% CI: 0.002-0.35; <em>P</em> = .011). Operative time was shorter with RIC (median: 292 [IQR: 274–315] vs. 330 [308–360] min; <em>p</em> = 0.00025). There were no differences in major complications (11.1 vs. 17.1%; <em>P</em> = .51) or minor complications (33.3 vs. 42.9%; <em>P</em> = .41), nor in hospital stay (11.5 vs. 9 days; <em>P</em> = .23). The median follow-up was 18 months (RIC) and 39 months (control).</div></div><div><h3>Conclusions</h3><div>In our series, RIC significantly reduced UAS without increasing morbidity and was associated with a shorter operative time compared with traditional techniques. The results support the anatomical consistency and reproducibility of the technique.</div></div>","PeriodicalId":94291,"journal":{"name":"Actas urologicas espanolas","volume":"50 4","pages":"Article 501934"},"PeriodicalIF":0.0,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147313902","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of surgical waiting list on oncological outcomes of radical prostatectomy in patients with intermediate- and high-risk prostate cancer","authors":"P. de Pablos-Rodríguez ,&nbsp;P. Guedes Oliva ,&nbsp;Á. Gómez Ferrer ,&nbsp;M. Beamud Cortés ,&nbsp;A. Wong Gutiérrez ,&nbsp;C. Gutiérrez Castañé ,&nbsp;A. Calatrava Fons ,&nbsp;J. Aliaga Patiño ,&nbsp;Á. García Cortés ,&nbsp;J. Agustín López ,&nbsp;A. Collado Serra ,&nbsp;V. Rodríguez Part ,&nbsp;J.L. Casanova Ramón Borja","doi":"10.1016/j.acuroe.2026.501910","DOIUrl":"10.1016/j.acuroe.2026.501910","url":null,"abstract":"<div><h3>Introduction</h3><div>The prognosis of localized prostate cancer (PCa) following radical treatment is generally favorable, although up to 46% of patients may still experience adverse outcomes. The impact of delayed surgery in intermediate-risk (IR) or high-risk (HR) patients remains under discussion. This study evaluates its association with oncological outcomes.</div></div><div><h3>Materials and methods</h3><div>Retrospective study of 2296 patients with IR and HR PCa who underwent radical prostatectomy (RP) between 1986 and 2025. Upgrading, upstaging, positive margins, PSA persistence, and lymph node involvement were analyzed. Waiting time was grouped into &lt;3, 3–6, and &gt;6 months.</div></div><div><h3>Results</h3><div>The median waiting time was 3.5 months. Eighty-five percent of patients were operated on within 6 months. At 5 years, no difference was detected between waiting time and time to biochemical recurrence (BCR) when comparing the &lt;3-month group with the 3–6-month group (HR 0.93; 95% CI 0.76–1.13) and the &gt;6 months group (HR 0.74; 95% CI 0.53–1.04) among IR patients. In HR patients, no differences were observed either: 3–6 months (HR 0.85; 95% CI 0.71–1.01) and &gt;6 months (HR 0.79; 95% CI 0.61–1.03). No increased risk of adverse pathological outcomes was found with longer delays.</div></div><div><h3>Conclusions</h3><div>A waiting time of ≤6 months was not associated with worse oncological prognosis, supporting its safety in IR or HR PCa.</div></div>","PeriodicalId":94291,"journal":{"name":"Actas urologicas espanolas","volume":"50 4","pages":"Article 501910"},"PeriodicalIF":0.0,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145907354","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictive factors for urethral stricture development in patients with bladder tumor: The role of intravesical BCG therapy","authors":"İsmail Emre Ergin ,&nbsp;Adem Sanci ,&nbsp;Emre Hepşen ,&nbsp;Kubilay Sarıkaya ,&nbsp;Metin Yığman ,&nbsp;Azmi Levent Sağnak ,&nbsp;Ahmet Nihat Karakoyunlu","doi":"10.1016/j.acuroe.2026.501908","DOIUrl":"10.1016/j.acuroe.2026.501908","url":null,"abstract":"<div><h3>Objective</h3><div>This study aims to investigate the predictive role of intravesical Bacillus Calmette-Guérin (BCG) therapy on urethral stricture development in male patients undergoing bladder tumor surveillance, while also assessing the impact of repeated urethral instrumentation on stricture risk.</div></div><div><h3>Methods</h3><div>This retrospective study included male patients aged 18–90 with non-muscle invasive bladder tumors followed between 2018 and 2024. Demographics, cystoscopy and TUR procedures, intravesical treatments (BCG and chemotherapy), and urethral stricture diagnosis were recorded. Urethral stricture was confirmed by uroflowmetry, cystoscopy, and urethrography. Patients with prior urethral stricture or incomplete records were excluded. Statistical analyses included logistic regression to identify predictors of stricture development, adjusting for age and comorbidities. Sample size was calculated to ensure adequate power to detect a 15% difference in stricture incidence related to BCG therapy.</div></div><div><h3>Results</h3><div>A total of 187 male patients were analyzed, with a 12.3% urethral stricture incidence. BCG therapy was administered to 32.6% of patients and significantly increased stricture risk (OR: 4.11, <em>P</em> = .015). Each additional dose was associated with an increased risk (OR: 2.11, <em>P</em> = .001). TURP (OR: 2.95, <em>P</em> = .045) and the number of cystoscopies (OR: 1.42 per procedure, <em>P</em> = .040) were also significant predictors. Tumor size ≥3 cm was associated with higher risk (OR: 1.88, <em>P</em> = .037). Spearman analysis showed positive correlations between stricture severity and both BCG doses and cystoscopy number.</div></div><div><h3>Conclusion</h3><div>Intravesical BCG therapy, repeated cystoscopies, and TURP increase urethral stricture risk in bladder tumor patients. Preventive measures and careful monitoring are essential to reduce urethral complications.</div></div>","PeriodicalId":94291,"journal":{"name":"Actas urologicas espanolas","volume":"50 4","pages":"Article 501908"},"PeriodicalIF":0.0,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145919547","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Is retroperitoneal access feasible using the single-port robotic platform for native nephrectomy after kidney transplantation?","authors":"H.B. Haberal ,&nbsp;F.M. Valenzi ,&nbsp;V. Santarelli ,&nbsp;S. Crivellaro","doi":"10.1016/j.acuroe.2025.501797","DOIUrl":"10.1016/j.acuroe.2025.501797","url":null,"abstract":"","PeriodicalId":94291,"journal":{"name":"Actas urologicas espanolas","volume":"50 4","pages":"Article 501797"},"PeriodicalIF":0.0,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144295595","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}